|
| Press Releases |
|
 |
|
| Wednesday, July 18, 2018 |
|
|
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ |
| This study was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and is the largest cardiovascular outcome trial conducted to date for a weight loss medication. more info >> |
|
| Wednesday, July 11, 2018 |
|
|
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan |
| Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018. more info >> |
|
| Tuesday, July 10, 2018 |
|
|
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018 |
| Eisai Co., Ltd. announces today that the results of the Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 will be presented in an oral session at the Alzheimer's Association International Conference (AAIC) 2018 held in Chicago. more info >> |
|
| Monday, July 9, 2018 |
|
|
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology |
| The 2-week double-blind clinical trial was a placebo-controlled, randomized, double-blind trial with 133 Japanese patients with chronic constipation. more info >> |
|
| Friday, July 6, 2018 |
|
|
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months |
| Eisai Co., Ltd. and Biogen Inc. announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. more info >> |
|
| Wednesday, July 4, 2018 |
|
|
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, July 2, 2018 |
|
|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
| The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. more info >> |
|
| Friday, June 22, 2018 |
|
|
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN) |
| Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. more info >> |
|
| Thursday, June 21, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL |
| AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. more info >> |
|
| Thursday, June 14, 2018 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
| Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
|
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
|
|
|
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering
Jul 11, 2025 08:28 HKT/SGT
|
|
|
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation 
Jul 11, 2025 07:00 HKT/SGT
|
|
|
XDS Datacentres and ICS Arabia partner to launch landmark 10MW Immersive Cooling Data Center in KSA
Jul 11, 2025 06:00 HKT/SGT
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 15:12 HKT/SGT
|
|
|
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA
Jul 10, 2025 12:30 HKT/SGT
|
|
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK
Jul 9, 2025 20:32 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
